Clinical Trial Update: Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Imiquimod combined with antimony-based immunochemotherapy for cutaneous leishmaniasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Antimony immunochemotherapy
• Imiquimod (imiquimod)

Snippet

Sponsor: Drugs for Neglected Diseases | Conditions: Cutaneous Leishmaniasis | Phase 3 | Status: COMPLETED